R715

R715 is a selective bradykinin B1 receptor antagonist. R715 significantly attenuates the hyperalgesic effect developed in Streptozotocin (HY-13753) -diabetic mice[1].

Product Specifications

CAS Number

[185052-09-9]

UNSPSC

12352209

Target

Bradykinin Receptor

Type

Peptides

Related Pathways

GPCR/G Protein

Applications

Neuroscience-Neuromodulation

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/r715.html

Purity

99.67

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N1[C@@H](CCC1)C(NCC(N[C@H](C(N[C@@H](CO)C(N[C@@H](C(N[C@H](C(O)=O)[C@@H](C)CC)=O)CC2=CC3=C(C=CC=C3)C=C2)=O)=O)CC4=CC=CC=C4)=O)=O)[C@H]5N(CCC5)C([C@H](CCCNC(N)=N)NC([C@@H](NC(C)=O)CCCCN)=O)=O

Molecular Formula

C57H81N13O12

Molecular Weight

1140.33

References & Citations

[1]Gabra BH, et al. Beneficial effect of chronic treatment with the selective bradykinin B1 receptor antagonists, R-715 and R-954, in attenuating streptozotocin-diabetic thermal hyperalgesia in mice. Peptides. 2003;24 (8) :1131-1139.